Heidrun Gevensleben

5.0k total citations
56 papers, 2.1k citations indexed

About

Heidrun Gevensleben is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Heidrun Gevensleben has authored 56 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 20 papers in Oncology and 18 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Heidrun Gevensleben's work include Epigenetics and DNA Methylation (16 papers), Prostate Cancer Treatment and Research (13 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Heidrun Gevensleben is often cited by papers focused on Epigenetics and DNA Methylation (16 papers), Prostate Cancer Treatment and Research (13 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Heidrun Gevensleben collaborates with scholars based in Germany, United States and United Kingdom. Heidrun Gevensleben's co-authors include Dimo Dietrich, Glen Kristiansen, Diane Goltz, Jörn Dietrich, Friedrich Bootz, Jörg Ellinger, Nicholas C. Turner, Jennifer Landsberg, Isaac García-Murillas and Alan Ashworth and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Heidrun Gevensleben

54 papers receiving 2.1k citations

Peers

Countries citing papers authored by Heidrun Gevensleben

Since Specialization

Citations

This map shows the geographic impact of Heidrun Gevensleben's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heidrun Gevensleben with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heidrun Gevensleben more than expected).

Fields of papers citing papers by Heidrun Gevensleben

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heidrun Gevensleben. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heidrun Gevensleben. The network helps show where Heidrun Gevensleben may publish in the future.

Co-authorship network of co-authors of Heidrun Gevensleben

This figure shows the co-authorship network connecting the top 25 collaborators of Heidrun Gevensleben. A scholar is included among the top collaborators of Heidrun Gevensleben based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heidrun Gevensleben. Heidrun Gevensleben is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Programmed Cell Death Ligand-1 (PDL-1) Correlates With Tumor Infiltration by Immune Cells and Represents a Promising Target for Immunotherapy in Endometrial Cancer 2022 ·Anticancer Research ·(unknown), Thore Thiesler, (unknown), (unknown), Florian Recker, Heidrun Gevensleben, Tim Müller, (unknown), Eva K. Egger, Rolf Fimmers, Matthias B. Stope, Glen Kristiansen, Alexander Mustea	9
2	Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancer 2021 ·Journal of Cancer Research and Clinical Oncology ·Lars Hanker, Ahmed El‐Balat, (unknown), Stefan Kommoss, Thomas Karn, Uwe Holtrich, Georgios Gitas, (unknown), Michael S. Anglesio, David G. Huntsman, Achim Rody, Heidrun Gevensleben, Friederike Hoellen	2
3	1O Detection of homologous recombination repair deficiency (HRD) in treatment-naive early triple-negative breast cancer (TNBC) by RAD51 foci and comparison with DNA-based tests 2021 ·Annals of Oncology ·(unknown), Alba Llop‐Guevara, Alex Pearson, Cristina Cruz, Marta Castroviejo‐Bermejo, Neha Chopra, Holly Tovey, Christy Toms, Divya Kriplani, Heidrun Gevensleben, Rebecca Roylance, Stephen Chan, Andrew Tutt, A. Skene, Abigail Evans, Helen Davies, Judith M. Bliss, Serena Nik‐Zainal, Judith Balmañà, Nicholas C. Turner	4
4	Novel pathogenic alterations in pediatric and adult desmoid-type fibromatosis – A systematic analysis of 204 cases 2020 ·Scientific Reports ·Marcel Trautmann, (unknown), Heidrun Gevensleben, Jessica Becker, Eva Wardelmann, Wolfgang Hartmann, Inga Grünewald, Sebastian Huss	28
5	Histotype-specific analysis of acid ceramidase expression in ovarian cancer 2020 ·Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·Ahmed El‐Balat, Thomas Karn, Uwe Holtrich, Sven Becker, Stefan Kommoss, Balázs Győrffy, Michael S. Anglesio, David G. Huntsman, (unknown), Achim Rody, Heidrun Gevensleben, Lars Hanker	4
6	CTLA4 methylation predicts response to anti–PD-1 and anti–CTLA-4 immunotherapy in melanoma patients 2018 ·JCI Insight ·Diane Goltz, Heidrun Gevensleben, Timo Vogt, (unknown), Carsten Golletz, Friedrich Bootz, Glen Kristiansen, Jennifer Landsberg, Dimo Dietrich	74
7	PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations 2018 ·EBioMedicine ·(unknown), Heidrun Gevensleben, Jörn Dietrich, Friedrich Bootz, Jennifer Landsberg, Diane Goltz, Dimo Dietrich	57
8	Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy 2018 ·Breast Cancer Research and Treatment ·Yuri Tolkach, Heidrun Gevensleben, Ralph A. Bundschuh, (unknown), (unknown), (unknown), (unknown), Mignon-Denise Keyver-Paik, Christina Kaiser, Hojjat Ahmadzadehfar, Markus Essler, Walther Kuhn, Glen Kristiansen	49
9	Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events 2017 ·Human Pathology ·Sebastian Huss, Helen Pasternack, Michaela A. Ihle, Sabine Merkelbach‐Bruse, Birthe Heitkötter, Wolfgang Hartmann, Marcel Trautmann, Heidrun Gevensleben, Reinhard Büttner, Hans‐Ulrich Schildhaus, Eva Wardelmann	50
10	Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients 2017 ·Clinical Epigenetics ·Luka de Vos, Heidrun Gevensleben, Andreas Schröck, Alina Franzen, Glen Kristiansen, Friedrich Bootz, Dimo Dietrich	38
11	The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib 2016 ·Cancer Immunology Immunotherapy ·Annkristin Heine, (unknown), Barbara T. Grünwald, Achim Krüger, Heidrun Gevensleben, Stefanie Andrea Erika Held, Natalio Garbi, Christian Kurts, Peter Brossart, Percy A. Knolle, Linda Diehl, Bastian Höchst	39
12	PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies 2016 ·Journal of Molecular Diagnostics ·Barbara Uhl, Heidrun Gevensleben, Yuri Tolkach, Verena Sailer, Michael Majores, Maria Jung, Sebastian Meller, Johannes Stein, Jörg Ellinger, Dimo Dietrich, Glen Kristiansen	38
13	Loss of the LIM-only protein Fhl2 impairs inflammatory reaction and scar formation after cardiac ischemia leading to better hemodynamic performance 2016 ·Life Sciences ·Diane Goltz, (unknown), Heidrun Gevensleben, Jutta Kirfel, Linda Diehl, Rainer Meyer, Reinhard Büttner	9
14	PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemia 2016 ·Leukemia ·Diane Goltz, Heidrun Gevensleben, (unknown), Jörn Dietrich, Glen Kristiansen, Jennifer Landsberg, Dimo Dietrich	69
15	The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer 2015 ·Clinical Cancer Research ·Heidrun Gevensleben, Dimo Dietrich, Carsten Golletz, Susanne Steiner, Maria Jung, Thore Thiesler, Michael Majores, Johannes Stein, Barbara Uhl, Stefan C. Müller, Jörg Ellinger, Carsten Stephan, Klaus Jung, Peter Brossart, Glen Kristiansen	167
16	Vancouver-Klassifikation von Nierentumoren: Empfehlungen der Konsenskonferenz der Internationalen Gesellschaft für Uropathologie (ISUP) 2012 2015 ·Der Pathologe ·Glen Kristiansen, Brett Delahunt, John R. Srigley, (unknown), (unknown), Heidrun Gevensleben, Thore Thiesler, Rodolfo Montironi, Lars Egevad	0
17	The Significance of Accurate Determination of Gleason Score for Therapeutic Options and Prognosis of Prostate Cancer 2015 ·Pathology & Oncology Research ·B. Helpap, (unknown), (unknown), (unknown), Jürgen Breul, Heidrun Gevensleben, Hans‐Helge Seifert	15
18	Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1 2012 ·Cancer Discovery ·Marieke Aarts, Rachel Sharpe, Isaac García-Murillas, Heidrun Gevensleben, Melissa S. Hurd, Stuart D. Shumway, Carlo Toniatti, Alan Ashworth, Nicholas C. Turner	252
19	Distinguishing medullary carcinoma of the breast from high‐grade hormone receptor‐negative invasive ductal carcinoma: an immunohistochemical approach 2010 ·Histopathology ·Uta Flucke, (unknown), Ludwig Hoy, (unknown), (unknown), Kerstin Rhiem, Rita K. Schmutzler, (unknown), Michael Braun, Susanne Steiner, Reinhard Buettner, Heidrun Gevensleben	12
20	Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers 2010 ·Archives of Gynecology and Obstetrics ·Kerstin Rhiem, Dolores Foth, Barbara Wappenschmidt, Heidrun Gevensleben, Reinhard Büttner, U. Ulrich, Rita K. Schmutzler	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact